Protocol Library

Each card lists peptide research notes — vial size, example research dose range, reconstitution example, frequency example, cycle length example, and risk level. All entries are educational. Not medical advice.

Research use only. Educational content. Not medical advice, diagnosis, treatment, or a personal recommendation. Not intended for human consumption. Always discuss with a qualified healthcare professional.

BPC-157

low risk

Commonly researched for tendon, ligament, gut lining and wound repair contexts.

Vial
5 mg
Dose
200–500 mcg daily (research literature)
Freq
1–2x daily (research example)
Cycle
4–8 weeks (research example)
recoverygut-healthjoint

Cartalax

low risk

Commonly researched for cartilage, connective-tissue and joint research models.

Vial
20 mg
Dose
Research literature commonly references 100–200 mcg per research day.
Freq
Once daily in research scheduling examples.
Cycle
10–20 days per research cycle, often repeated 2–3 times per year in published bioregulator protocols.
jointbioregulatorsrecovery

CJC-1295 (no DAC)

low risk

Researched in growth hormone pulse research, often paired with GHRPs.

Vial
2 mg
Dose
100 mcg per use (research literature)
Freq
1–3x daily (research example)
Cycle
8–12 weeks (research example)
recoverymuscle-growthskin-hair

CJC-1295 with DAC

moderate risk

Researched in studies of sustained GH/IGF-1 elevation.

Vial
2 mg
Dose
1–2 mg weekly (research literature)
Freq
1–2x weekly (research example)
Cycle
8–12 weeks (research example)
muscle-growthrecoveryskin-hair

GHK-Cu

low risk

Researched in dermal repair, hair follicle, and anti-aging contexts.

Vial
50 mg
Dose
1–2 mg per use (research literature)
Freq
Topical or subq (research example)
Cycle
4–8 weeks (research example)
skin-hairrecoverylongevity

GHRP-2

moderate risk

Investigated for pulsatile growth hormone release via ghrelin receptor agonism.

Vial
5 mg lyophilized vial
Dose
Commonly discussed research range: 100–300 mcg per administration.
Freq
2–3x daily in research designs.
Cycle
8–12 week educational example.
muscle-growthrecoveryperformance

GHRP-6

moderate risk

Investigated for GH pulsatility and appetite signaling via ghrelin receptor agonism.

Vial
5 mg lyophilized vial
Dose
Commonly discussed research range: 100–300 mcg per administration.
Freq
2–3x daily in research designs.
Cycle
8–12 week educational example.
muscle-growthrecoveryperformance

GLOW Blend (BPC-157 + TB-500 + GHK-Cu)

moderate risk

Studied as a combined research peptide profile for repair-related endpoints.

Vial
Blend vial (varies by source)
Dose
Educational research dose example only.
Freq
Daily or alternating-day research designs.
Cycle
4–8 week educational example.
recoveryskin-hairjoint

IGF-1 DES

high risk

Investigated for local IGF-1 receptor activity with reduced IGFBP binding.

Vial
1 mg lyophilized vial
Dose
Commonly discussed research range: 50–100 mcg per site.
Freq
Site-specific in research designs.
Cycle
4 week educational example.
muscle-growthperformancerecovery

IGF-1 LR3

high risk

Studied for its role in IGF-1 pathway research, cellular growth signaling and muscle-research models.

Vial
1 mg
Dose
Published research literature commonly cites 20–50 mcg per research day in cellular and animal study ranges.
Freq
Once daily in research scheduling examples.
Cycle
Short research cycles (commonly 4–6 weeks).
muscle-growthgrowth-factorrecovery

Ipamorelin

low risk

Researched as a selective ghrelin receptor agonist in GH studies.

Vial
5 mg
Dose
100–300 mcg per use (research literature)
Freq
1–3x daily (research example)
Cycle
8–12 weeks (research example)
recoverymuscle-growthskin-hair

PEG-MGF

moderate risk

Investigated for myogenic precursor activation via MGF/IGF-1Ec splice variant pathway.

Vial
2 mg lyophilized vial
Dose
Commonly discussed research range: 200–400 mcg per administration.
Freq
2–3x weekly in research designs.
Cycle
4–6 week educational example.
muscle-growthrecoveryperformance

Sermorelin

low risk

Researched as a GHRH analog in pituitary GH release studies.

Vial
5 mg
Dose
100–300 mcg per use (research literature)
Freq
Nightly (research example)
Cycle
8–12 weeks (research example)
recoverymuscle-growthsleep

TB-500

moderate risk

Researched in soft tissue, muscle, and vascular repair contexts.

Vial
5 mg
Dose
2–5 mg weekly (research literature)
Freq
1–2x weekly (research example)
Cycle
4–6 weeks (research example)
recoveryjoint
Verified Research Supplier

Looking for a research supplier?

Enhanced Performance is a separate research supply platform. Visiting or purchasing is optional and not required to use PepToolbox.

Disclosure: Enhanced Performance is a separate platform connected to the owner of this website. Purchasing is optional and not required to use this tool.